Belgium· BE-AMP-SAM662133-00
Eylea 114.3 mg/ml
A aflibercept product containing aflibercept, registered in Belgium by Bayer. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Aflibercept is registered in 11 of 19 countries.
Countries holding a registration under ATC S01LA05 (aflibercept), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Aflibercept · ATC S01LA05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Aflibercept
- Manufacturer
- Bayer
- Country
- Belgium (BE)
- ATC code
- S01LA05
- ATC class
- Aflibercept
- Defined daily dose
- 0.018 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aflibercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenEylea 114,3 mg/ml Injektionsvätska, lösningBayer AG
- CzechiaEYLEABayer AG, Leverkusen
- SpainEYLEA 114,3 MG/ML SOLUCION INYECTABLEBayer Ag
- FranceEYLEA 114,3 mg/mL, solution injectableBAYER AG (ALLEMAGNE)
- IrelandEylea 114.3 mg/ml solution for injectionBayer AG
- IcelandEyleaBayer AG*
- NetherlandsEylea 114,3 mg/ml oplossing voor injectieBayer AG
- NorwayEyleaBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Vgenfli
- Iceland · Afiveg, Afqlir
- Liechtenstein · Afiveg, Afqlir
- Norway · Afiveg, Afqlir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ebba73b0-22b6-4bf5-b44e-d49e673f99c2 GET /v1/drugs/ebba73b0-22b6-4bf5-b44e-d49e673f99c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Eylea 114.3 mg/ml",
"name_fr": "Eylea 114.3 mg/ml",
"name_nl": "Eylea 114.3 mg/ml",
"amp_code": "SAM662133-00",
"strengths": [
"114.3000",
"114.3000"
],
"pack_count": 1,
"substances": [
"Aflibercept",
"Sucrose",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Aflibercept",
"authorisation_numbers": [
"EU/1/12/797/003"
]
}See everything about aflibercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.